The expansion of Nautilus’ footprint into one of the largest biotechnology and pharmaceutical hubs in the country capitalizes on the company’s growing scientific and business momentum. The state-of-the-art facilities feature laboratory and office space that increases Nautilus’ capacity for research and development, engineering, software development, and other key functions that will enable the company to further develop its single-molecule proteomics platform.
“We are excited to establish a third location for our growing team, extending beyond
Nautilus is developing a next-generation protein analysis platform with the potential to comprehensively measure the proteome at the single-molecule level. The company recently announced a research collaboration with the
About
With its corporate headquarters in
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations with respect to the suitability of the Nautilus product platform to investigate proteins and proteoforms; and expectations with respect to the functionality and performance of Nautilus’ product platform, its potential impact on pharmaceutical development and drug discovery. These statements are based on numerous assumptions concerning the development of Nautilus’ products and target markets and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in the Registration Statement on Form S-1 filed with the
Media Contact
Press@nautilus.bio
Investor Contact
InvestorRelations@nautilus.bio
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/4403d343-3ee7-4815-8298-cc798f4d04a3
https://www.globenewswire.com/NewsRoom/AttachmentNg/ba91d75e-0c30-4882-849c-52c8b16c5e90
![](https://ml.globenewswire.com/media/NzY0YWRhM2MtOTAyMy00NTIyLWI5OWUtOWNiNGQ0MmU2ZGU2LTEyMTk4NjU=/tiny/Nautilus-Biotechnology-Inc-.png)
Nautilus Biotechnology - San Diego
![](https://ml.globenewswire.com/media/4403d343-3ee7-4815-8298-cc798f4d04a3/medium/nautilus-biotechnology-san-diego.png)
University Town Center in San Diego, California
Nick Nelson
![](https://ml.globenewswire.com/media/ba91d75e-0c30-4882-849c-52c8b16c5e90/medium/nick-nelson.jpg)
SVP and Chief Business Officer
2023 GlobeNewswire, Inc., source